MediPrint Ophthalmics

Executive Summary

MediPrint Ophthalmics is a clinical-stage pharmaceutical company pioneering a novel drug delivery platform that prints FDA-approved drugs onto contact lenses, enabling sustained release for the treatment of glaucoma, dry eye, and ocular allergies. Based in San Diego, the company aims to address key limitations of traditional eye drops, such as poor patient compliance, inconsistent dosing, and peak-and-trough drug levels. Its lead programs are in Phase 2 development, with a focus on establishing proof of concept for its drug-eluting contact lens technology. By leveraging an existing FDA-approved drug library and a proprietary printing process, MediPrint seeks to create differentiated therapies that improve efficacy, convenience, and adherence. The platform has the potential to be extended to other ophthalmic conditions and even non-ophthalmic indications, offering a versatile drug delivery solution. The company has not yet disclosed specific financials or valuation, but its clinical progress and innovative approach position it as an attractive target for partnerships with larger ophthalmic firms. Key near-term milestones include the completion of Phase 2 trials for its lead candidates, which could de-risk the platform and provide pivotal clinical data. If successful, MediPrint could capture a significant share of the multi-billion-dollar glaucoma and dry eye markets. However, the company faces technical and regulatory challenges, including manufacturing scalability and long-term safety of drug-eluting contact lenses. Given its early stage and lack of disclosed partnerships, MediPrint represents a speculative but potentially high-reward investment opportunity in the ophthalmic drug delivery space.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 trial data readout for glaucoma candidate50% success
• Q4 2026Phase 2 trial initiation or data update for dry eye candidate40% success
• TBDPartnership or licensing deal with major ophthalmic company30% success